当前位置: 首页 >> 检索结果
81. Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
作者: Jesper Kjaergaard.;Christian Holdflod Møller.;Sebastian Wiberg.;Astrid Duus Mikkelsen.;Hasse Møller-Sørensen.;Hanne Berg Ravn.;Jesper Ravn.;Peter Skov Olsen.;Dan E Høfsten.;Søren Boesgaard.;Lars Køber.;Jens Christian Nilsson.;Christian Hassager.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014961页
GLP-1 (glucagon-like peptide-1) agonists have been proven beneficial in reducing the risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted cardiac surgery is unknown. This trial aimed to investigate the efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducing the risk of death and major organ failure.
82. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
83. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure.
作者: Michael R Zile.;William T Abraham.;Lynne W Stevenson.;Maria Rosa Costanzo.;Christiane E Angermann.;Mandeep R Mehra.;Akshay S Desai.;Anique Ducharme.;Nessa Johnson.;John Henderson.;JoAnn Lindenfeld.
来源: Circ Heart Fail. 2025年18卷6期e012754页
Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity. These improved outcomes were associated with a reduction in PA pressure. However, several pivotal questions remain unanswered: do systolic, diastolic, or mean PA pressures each predict all-cause mortality? Do PA pressures predict mortality across the ejection fraction (EF) spectrum? Do increases or decreases in PA pressure over time predict increases or decreases in mortality?
84. Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial.
作者: Gaoqiang Xie.;Anushka Patel.;Xin Du.;Yihong Sun.;Xian Li.;Tao Wu.;Zhixin Hao.;Runlin Gao.;Yangfeng Wu.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011441页
Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge.
85. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
86. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
87. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
88. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
作者: Jung-Kyu Han.;Keehwan Lee.;Sang-Hyeon Park.;Seokhun Yang.;Doyeon Hwang.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Yong Hoon Kim.;Namho Lee.;Seung Jin Lee.;Sanghoon Shin.;Hyo-Soo Kim.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014623页
The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI.
89. Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial.
作者: Varsha Keelara Tanguturi.;Roukoz Abou-Karam.;Fangzhou Cheng.;Rong Duan.;Ignacio Inglessis-Azuaje.;Nathaniel B Langer.;Evin N Yucel.;Jonathan J Passeri.;Judy W Hung.;Sammy Elmariah.
来源: Circulation. 2025年151卷21期1498-1507页
Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year.
90. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
作者: Sunil V Rao.;Maria Mori Brooks.;Helen E A D'Agostino.;P Gabriel Steg.;Tabassome Simon.;Herbert D Aronow.;Andrew M Goldsweig.;Shahbaz Malik.;Caroline Alsweiler.;Kalon K L Ho.;Payam Dehghani.;Adriano Caixeta.;Ata R Quraishi.;Simon Robinson.;Jay H Traverse.;Omar Siddiqi.;Dean A Fergusson.;Brian J Potter.;Joshua Schulman-Marcus.;Friederike K Keating.;Jeffrey L Carson.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e015249页
The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/dL) red blood cell transfusion. The results suggested a benefit on 30-day death or MI with a liberal transfusion strategy. The effect of transfusion in patients with acute MI undergoing revascularization is unclear.
91. Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.
作者: Saibal Kar.;Raj R Makkar.;Brian K Whisenant.;Nadira Hamid.;Hursh Naik.;Peter Tadros.;Matthew J Price.;Gagan Singh.;Jonathan G Schwartz.;Samir Kapadia.;Oluseun Alli.;Samuel Horr.;Puvi Seshiah.;Wayne Batchelor.;Brandon M Jones.;Mustafa I Ahmed.;Raymond Benza.;Ulrich Jorde.;Vinod H Thourani.;Andrew A Ghobrial.;Gilbert H L Tang.;Phillip M Trusty.;Dina Huang.;Rebecca T Hahn.;David H Adams.;Paul Sorajja.; .
来源: Circulation. 2025年151卷23期1630-1638页
One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER.
92. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
作者: Nikolaus Marx.;John E Deanfield.;Johannes F E Mann.;Rosario Arechavaleta.;Stephen C Bain.;Harpreet S Bajaj.;Katrine Bayer Tanggaard.;Andreas L Birkenfeld.;John B Buse.;Zaklina Davicevic-Elez.;Cyrus Desouza.;Scott S Emerson.;Mads D M Engelmann.;G Kees Hovingh.;Silvio E Inzucchi.;Pardeep S Jhund.;Sharon L Mulvagh.;Rodica Pop-Busui.;Neil R Poulter.;Søren Rasmussen.;Shih-Te Tu.;Darren K McGuire.; .
来源: Circulation. 2025年151卷23期1639-1650页
Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes.
93. Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.
作者: Mohammadreza Naderian.;Marwan E Hamed.;Ali A Vaseem.;Kristjan Norland.;Ozan Dikilitas.;Azin Teymourzadeh.;Kent R Bailey.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2025年18卷2期e004968页
In the Myocardial Infarction Genes clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRSg], n=104) that additionally included a polygenic risk score. After 6 months, IRSg participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).
94. Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.
作者: Javier Jimenez.;Hanyu Ni.;Stuart D Katz.;Garrie J Haas.;Jinwen Cao.;Muni Rubens.;Sandra Chaparro.;Anshul Saxena.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Palak Shah.;Jane E Wilcox.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Jonathan O Mead.;Natalie Hurst.;Patricia K Parker.;Gordon S Huggins.;Elizabeth Jordan.;Daniel D Kinnamon.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年18卷2期e004946页
Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.
95. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
作者: Andrew M Goldsweig.;William J Kostis.;Brandon M Herbert.;Claire Bouleti.;Brian J Potter.;Jordan B Strom.;Jocelyne Benatar.;Thao Huynh.;Srikanth Vallurupalli.;Estêvão Lanna Figueiredo.;J Dawn Abbott.;Howard A Cooper.;Andrew P DeFilippis.;Dean A Fergusson.;Shaun G Goodman.;Paul C Hébert.;Renato D Lopes.;Sunil V Rao.;Tabassome Simon.;Jeffrey L Carson.;Maria Mori Brooks.;John H Alexander.; .
来源: Circ Heart Fail. 2025年18卷4期e012495页
Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal transfusion strategy on outcomes in patients with MI and anemia with and without baseline HF.
96. Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
作者: Yunpeng Zhu.;Wei Zhang.;Kaijie Qin.;Yun Liu.;Haoyi Yao.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Mario Gaudino.;Qiang Zhao.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014542页
The optimal antispastic treatment after coronary artery bypass grafting using radial artery (RA) grafts is controversial. This clinical trial aimed to generate pilot comparative data on the effects of nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
97. Enhancing Stroke Awareness and Activation Among High-Risk Populations: A Randomized Direct Mail Intervention in Diverse Healthcare Settings.
作者: Christine C Groves.;Teresa M Damush.;Laura J Myers.;Fitsum Baye.;Joanne K Daggy.;Anthony J Perkins.;Holly Martin.;Layne Mounsey.;Daniel O Clark.;Linda S Williams.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011425页
Many patients are unaware of their stroke risk. The purpose of this research was to compare the effect of behaviorally tailored mailed messages on patient activation to reduce stroke risk.
98. Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study.
作者: Richard Casazza.;Bilal Malik.;Arsalan Hashmi.;Joshua Fogel.;Enrico Montagna.;Robert Frankel.;Elliot Borgen.;Sergey Ayzenberg.;Michael Friedman.;Norbert Moskovits.;Shivani Verma.;Jamie Meng.;Nailun Chang.;Yili Huang.;Carlos Rodriguez.;Habib Hymie Chera.;Shiv Raj.;Saurav Chaterjee.;Daren Gibson.;Andres Palacios.;Chirag Agarwal.;Maria Victoria Nene.;Jacob Shani.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014602页
Radiation exposure is one of the most adverse occupational hazards faced by interventional cardiologists. Various arterial access sites have shown to yield different operator radiation exposure during diagnostic cardiac catheterization.
99. Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia.
作者: Michael S Conte.;Alik Farber.;Andrew Barleben.;Emiliano Chisci.;Gheorghe Doros.;Vikram S Kashyap.;Ahmed Kayssi.;Philippe Kolh.;Carla C Moreira.;Timothy Nypaver.;Kenneth Rosenfield.;Vincent L Rowe.;Andres Schanzer.;Niten Singh.;Jeffrey J Siracuse.;Michael B Strong.;Matthew T Menard.
来源: Circ Cardiovasc Interv. 2025年18卷3期e014716页
The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment.
100. Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial.
作者: Jinhwan Jo.;Sang Yoon Lee.;Woochan Kwon.;Seung-Jae Lee.;Jong-Young Lee.;Seung Hun Lee.;Doosup Shin.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Ki Hong Choi.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.;Sang Yeub Lee.;Joo Myung Lee.; .
来源: Circ Cardiovasc Interv. 2025年18卷3期e014952页
Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.
|